M&A

News

J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular

Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.

News

GSK confirms plan to buy cancer firm IDRx for $1bn

GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

News

Biogen offers to buy out wilting Sage for $442 million

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae.

News

Is GSK prepping a $1bn takeover bid for IDRx?

GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.

News

Galapagos' chief executive Paul Stoffels

Galapagos unveils plan to split, hiving off its drugs unit

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.

Market Access

Graphic of an upward trajectory arrow with woman and telescope atop

The biopharma outlook for 2025: Opportunities and challenges

With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how cap

J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular

GSK confirms plan to buy cancer firm IDRx for $1bn

Biogen offers to buy out wilting Sage for $442 million

Is GSK prepping a $1bn takeover bid for IDRx?

Galapagos unveils plan to split, hiving off its drugs unit

The biopharma outlook for 2025: Opportunities and challenges

On genomics, NGS, and doing much more good than bad, with Ma...

How to meet your physicians where they are online

M&A

Editor's Picks